nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—Decreased appetite—Fludarabine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Raltegravir—Visual impairment—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Raltegravir—Fatigue—Fludarabine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Raltegravir—Inflammation—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Raltegravir—Hallucination—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Raltegravir—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Raltegravir—Pain—Fludarabine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Raltegravir—Constipation—Fludarabine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Raltegravir—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Raltegravir—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Raltegravir—Urethral disorder—Vincristine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Raltegravir—Eye disorder—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Raltegravir—Hypersensitivity—Teniposide—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Raltegravir—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Raltegravir—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Raltegravir—Anaemia—Bleomycin—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Raltegravir—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Raltegravir—Asthenia—Teniposide—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Raltegravir—Malaise—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Raltegravir—Pruritus—Teniposide—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Raltegravir—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Raltegravir—Cardiac disorder—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Raltegravir—Alopecia—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Raltegravir—Body temperature increased—Fludarabine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Raltegravir—Mental disorder—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Raltegravir—Malnutrition—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Raltegravir—Erythema—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Raltegravir—Cough—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Raltegravir—Angiopathy—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Raltegravir—Diarrhoea—Teniposide—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Raltegravir—Mediastinal disorder—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Raltegravir—Chest pain—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Raltegravir—Myalgia—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Raltegravir—Alopecia—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Raltegravir—Back pain—Carmustine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Raltegravir—Discomfort—Bleomycin—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Raltegravir—Mental disorder—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Raltegravir—Chills—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Raltegravir—Neoplasm—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Raltegravir—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Raltegravir—Alopecia—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Raltegravir—Confusional state—Bleomycin—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Raltegravir—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Raltegravir—Tremor—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Raltegravir—Erythema—Mitoxantrone—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Raltegravir—Infection—Bleomycin—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Raltegravir—Anaemia—Carmustine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Raltegravir—Back pain—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Raltegravir—Vomiting—Teniposide—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Raltegravir—Agitation—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Raltegravir—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Raltegravir—Asthenia—Fludarabine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Raltegravir—Rash—Teniposide—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Raltegravir—Dermatitis—Teniposide—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Raltegravir—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Raltegravir—Headache—Teniposide—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Raltegravir—Pruritus—Fludarabine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Raltegravir—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Raltegravir—Back pain—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Raltegravir—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Raltegravir—Anaemia—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Raltegravir—Agitation—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Raltegravir—Diarrhoea—Fludarabine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Raltegravir—Hypertension—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Raltegravir—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Raltegravir—Nausea—Teniposide—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Raltegravir—Anaemia—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Raltegravir—Vertigo—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Raltegravir—Hepatic failure—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Raltegravir—Chest pain—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Raltegravir—Myalgia—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Raltegravir—Anxiety—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Raltegravir—Paraesthesia—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Raltegravir—Malaise—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Raltegravir—Hypertension—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Raltegravir—Confusional state—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Raltegravir—Decreased appetite—Bleomycin—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Raltegravir—Myalgia—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Raltegravir—Cough—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Raltegravir—Infection—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Raltegravir—Vomiting—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Raltegravir—Rash—Fludarabine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Raltegravir—Dermatitis—Fludarabine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Raltegravir—Hypertension—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Raltegravir—Pain—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Raltegravir—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Raltegravir—Headache—Fludarabine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Raltegravir—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Raltegravir—Myalgia—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Raltegravir—Chest pain—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Raltegravir—Anxiety—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Raltegravir—Lethargy—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Raltegravir—Discomfort—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Raltegravir—Infection—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Raltegravir—Feeling abnormal—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Raltegravir—Confusional state—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Raltegravir—Nervous system disorder—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Raltegravir—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Raltegravir—Nausea—Fludarabine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Raltegravir—Infection—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Raltegravir—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Raltegravir—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Raltegravir—Urticaria—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Raltegravir—Body temperature increased—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Raltegravir—Insomnia—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Raltegravir—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Raltegravir—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Raltegravir—Paraesthesia—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Raltegravir—Mood swings—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Raltegravir—Somnolence—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Raltegravir—Decreased appetite—Carmustine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Raltegravir—Insomnia—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Raltegravir—Paraesthesia—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Raltegravir—Constipation—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Raltegravir—Pain—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Raltegravir—Breast disorder—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Raltegravir—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Raltegravir—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Raltegravir—Decreased appetite—Vincristine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Raltegravir—Somnolence—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Raltegravir—Feeling abnormal—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Raltegravir—Fatigue—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Raltegravir—Asthenia—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Raltegravir—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Raltegravir—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Raltegravir—Pain—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Raltegravir—Constipation—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Raltegravir—Pruritus—Bleomycin—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Raltegravir—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Raltegravir—Eosinophilia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Raltegravir—Fatigue—Mitoxantrone—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Raltegravir—Constipation—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Raltegravir—Pain—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Raltegravir—Abdominal pain—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Raltegravir—Body temperature increased—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Raltegravir—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Raltegravir—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Raltegravir—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Raltegravir—Neutropenia—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Raltegravir—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Raltegravir—Abdominal pain—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Raltegravir—Body temperature increased—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Raltegravir—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Raltegravir—Urticaria—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Raltegravir—Hypersensitivity—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Raltegravir—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Raltegravir—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Raltegravir—Vomiting—Bleomycin—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Raltegravir—Infestation—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Raltegravir—Infestation NOS—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Raltegravir—Depression—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Raltegravir—Rash—Bleomycin—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Raltegravir—Dermatitis—Bleomycin—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Raltegravir—Asthenia—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Raltegravir—Renal failure—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Raltegravir—Hypersensitivity—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Raltegravir—Haematuria—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Raltegravir—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Raltegravir—Epistaxis—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Raltegravir—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Raltegravir—Asthenia—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Raltegravir—Diarrhoea—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Raltegravir—Nausea—Bleomycin—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Raltegravir—Asthenia—Mitoxantrone—lymphatic system cancer	0.000992	0.000992	CcSEcCtD
Raltegravir—Dizziness—Carmustine—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Raltegravir—Diarrhoea—Vincristine—lymphatic system cancer	0.000971	0.000971	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Raltegravir—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Raltegravir—Urethral disorder—Methotrexate—lymphatic system cancer	0.00095	0.00095	CcSEcCtD
Raltegravir—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000946	0.000946	CcSEcCtD
Raltegravir—Vomiting—Carmustine—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Raltegravir—Dizziness—Vincristine—lymphatic system cancer	0.000938	0.000938	CcSEcCtD
Raltegravir—Rash—Carmustine—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Raltegravir—Dermatitis—Carmustine—lymphatic system cancer	0.000936	0.000936	CcSEcCtD
Raltegravir—Visual impairment—Methotrexate—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Raltegravir—Headache—Carmustine—lymphatic system cancer	0.000931	0.000931	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000916	0.000916	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—lymphatic system cancer	0.000906	0.000906	CcSEcCtD
Raltegravir—Tinnitus—Methotrexate—lymphatic system cancer	0.000904	0.000904	CcSEcCtD
Raltegravir—Vomiting—Vincristine—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Raltegravir—Rash—Vincristine—lymphatic system cancer	0.000895	0.000895	CcSEcCtD
Raltegravir—Dermatitis—Vincristine—lymphatic system cancer	0.000894	0.000894	CcSEcCtD
Raltegravir—Headache—Vincristine—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Raltegravir—Nausea—Carmustine—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Raltegravir—Vomiting—Mitoxantrone—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Raltegravir—Immune system disorder—Methotrexate—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Raltegravir—Rash—Mitoxantrone—lymphatic system cancer	0.000871	0.000871	CcSEcCtD
Raltegravir—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000871	0.000871	CcSEcCtD
Raltegravir—Chills—Methotrexate—lymphatic system cancer	0.00087	0.00087	CcSEcCtD
Raltegravir—Headache—Mitoxantrone—lymphatic system cancer	0.000866	0.000866	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—lymphatic system cancer	0.000849	0.000849	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Raltegravir—Erythema—Methotrexate—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Raltegravir—Nausea—Vincristine—lymphatic system cancer	0.000843	0.000843	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—lymphatic system cancer	0.000826	0.000826	CcSEcCtD
Raltegravir—Nausea—Mitoxantrone—lymphatic system cancer	0.000821	0.000821	CcSEcCtD
Raltegravir—Back pain—Methotrexate—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000783	0.000783	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—lymphatic system cancer	0.00078	0.00078	CcSEcCtD
Raltegravir—Malaise—Methotrexate—lymphatic system cancer	0.000761	0.000761	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Raltegravir—Cough—Methotrexate—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000713	0.000713	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—lymphatic system cancer	0.00071	0.00071	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—lymphatic system cancer	0.000694	0.000694	CcSEcCtD
Raltegravir—Infection—Methotrexate—lymphatic system cancer	0.000684	0.000684	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000675	0.000675	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000674	0.000674	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—lymphatic system cancer	0.000669	0.000669	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000666	0.000666	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—lymphatic system cancer	0.000623	0.000623	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—lymphatic system cancer	0.000618	0.000618	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—lymphatic system cancer	0.000612	0.000612	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—lymphatic system cancer	0.000606	0.000606	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—lymphatic system cancer	0.000599	0.000599	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000594	0.000594	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—lymphatic system cancer	0.000594	0.000594	CcSEcCtD
Raltegravir—Pain—Methotrexate—lymphatic system cancer	0.000589	0.000589	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000563	0.000563	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—lymphatic system cancer	0.000547	0.000547	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Raltegravir—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000507	0.000507	CcSEcCtD
Raltegravir—Asthenia—Methotrexate—lymphatic system cancer	0.000494	0.000494	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—lymphatic system cancer	0.000487	0.000487	CcSEcCtD
Raltegravir—Diarrhoea—Methotrexate—lymphatic system cancer	0.000471	0.000471	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Raltegravir—Rash—Methotrexate—lymphatic system cancer	0.000434	0.000434	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—lymphatic system cancer	0.000434	0.000434	CcSEcCtD
Raltegravir—Headache—Methotrexate—lymphatic system cancer	0.000431	0.000431	CcSEcCtD
Raltegravir—Nausea—Methotrexate—lymphatic system cancer	0.000409	0.000409	CcSEcCtD
